AccuFusion™ RNA Lung Cancer Panel
For Research Use Only. Not for use in diagnostic procedures.
Known fusion detection and research via amplicon-based target enrichment for Next Generation Sequencing (NGS) on Illumina sequencing platforms
AccuFusion™ RNA Lung Cancer Panel uses a dual primer amplification method to enable focused detection of more than 280 known gene fusions associated with non-small cell lung cancer (NSCLC).
Fusion genes are associated with ALK, CIT, EML4, FGFR1, MBIP, MET, NRG1, NTRK1, NTRK3, PDGFRA, RET, ROS1, TACC3.
The AccuFusion dual-primer based amplification technology uses expertly designed and target specific primers to generate libraries without fragmentation of the input material.
Compared to other methods such as qPCR, FISH, or Sanger sequencing, Paragon Genomics targeted fusion sequencing method allows robust multiplexed detection of variants using minimum sample input and a simple workflow.
Fast and reliable assay for detecting known gene fusions
Sensitive Detection
Can detect down to 1% variant frequency with high confidence.
Excellent performance with high on-target rate
Prepare high-quality targeted NGS libraries using AccuFusion RNA Fusion Technology to achieve high on-target rate for efficient sequencing
Fast, streamlined workflow
Generate sequencing-ready libraries in just 6 hours using a rapid, four-step protocol from extracted RNA to sequence ready libraries.
Targeted identification of RNA fusions associated with lung cancer
Interrogate ~280 known RNA fusions using a target-specific dual-primer multiplex PCR method.
Specifications
SKU
Description
Pack Size
SKU
Description
Pack Size
917103
AccuFusion RNA Lung Cancer Panel
8 reactions
SKU
Description
Pack Size
917104
AccuFusion RNA Lung Cancer Panel
96 reaction
SKU
Description
Pack Size
917105
AccuFusion RNA Lung Cancer Panel
384 reaction
SKU
Description
Pack Size
716006
CleanPlex® Dual-Indexed PCR Primers for Illumina® Set A
96 indexes, 96 reactions
Your content has been submitted